UKMF

Congratulations to the winners of the bursaries below. These are joint awards with some of our Platinum sponsors. The bursaries covered the registration fee for ASH Virtual in December 2020.  Thank you to our Platinum sponsors:

The Binding Site – Oliver Cohen

Amgen – Aikaterini Kazantzi

Takeda – Nadjoua Maouche 

The winners have kindly written a review of ASH 20, which can be found below in the conference reports.

Congratulations to the recipients of the UKMF Travel Bursary to the ASH in Orlando in December 2019.  Thank you to our Platinum Sponsors for jointly awarding these travel bursaries to:

1. 1. Alexia Katsarou – Celgene
   2. Ana Martins Metelo  – Takeda

The recipients of the travel grant have written a review of the meeting. Dr Guy Pratt and Dr Rakesh Popat have also produced a report from ASH.

Conference reports can be found below. Thank you to the contributors.

Congratulations to the recipients of the UKMF Travel Bursary to the IMW meeting in Boston, September 2019.  Thank you to our Platinum Sponsors for jointly awarding these travel bursaries.

1. Wei Yee Chan – Binding Site
2. Firas Al-Kaisi – Takeda
3. Roisin McAvera – Celgene
4. Sarah Bird – Amgen

The recipients of the travel grant have written a review of the meeting, which can be found below.

Thank you also to Dr Rachel Hall and Dr Guy Pratt for their review from this meeting. This can also be found in the documents below.

We wish to thank Dr Richard Soutar and Dr Guy Pratt for producing a review from EHA Stockholm in June 2018.

The following reports from ASH Atlanta 2017 were kindly provided by the recipients of the UKMF travel bursaries.

Thank you to the UKMF bursary winners for their IMW roundup.

Thank you to Dr Guy Pratt and Dr Ceri Bygrave for their review from ASH, San Diego 2016.

Sarah Essex was awarded a UKMF travel bursary to attend the 2013 IMW meeting in Kyoto. She has kindly reviewed this meeting in the attached document.

Dr Lorenzo Melchor is a postdoctoral researcher and Dr Annamaria Brioli is a clinical research fellow at The Institute of Cancer Research and they were  awarded a travel bursary to attend the ASH meeting in Atlanta in December 2013. They have written a brief report of their experience from this meeting.

Meeting organisers, Professors Franco Dammacco and Angelo Vacca, assembled an impressive group of speakers for this enjoyable and informative meeting in the southern Italian Adriatic coastal city of Bari. Europe and the US were well represented by familiar key note speakers including Michel Attal, Herve Avet-Loiseau, Jean-Luc Harrouseau, Hartmut Goldschmidt, Michel Cavo, Antonio Palumbo, Pieter Sonneveld, David Roodman and Kenneth Anderson. Unfortunately, only the UK lacked senior representation from the UK myeloma community.

Michel Attal espoused once more the ‘new European emerging paradigm’ for intensive treatment comprising induction, autograft (+/- 2nd autograft), consolidation and maintenance. His other familiar proposition, strongly endorsed by Antonio Palumbo, was that achieving CR is becoming an increasingly feasible and desirable objective providing additional rationale for the use of the newer agents as first line induction therapy. He conceded that the optimal combination regimen for induction therapy was not yet established but did propose that Bortezomib and IMID based combinations may well prove superior. He also con
This meeting delivered a broad curriculum of current myeloma clinical practice and cutting edge new therapeutic strategies giving credence to Dr Anderson prediction that‘myeloma will become a chronic illness with complete responses in a significant fraction’ceded that it is currently unproven whether a second autograft is worthwhile, although in many cases it is clearly feasible. Furthermore, controversy continues as to whether the second autograft should be given early or late ie after relapse and re-induction. The UK Myeloma X trial will provide important evidence in this debate. Maintenance strategies have compared Bortezomib and lenalidomide although the latter agent appears the preferred option. Given these considerations, with the possible exception of the consolidation issue, the UK Myeloma XI Trial appears well designed and likely to address many of these issues.

Kenneth Anderson summarised novel therapies and new targets under development at the Dana Faber Cancer Institute. Key approaches included immunotherapy approaches including elotuzumab, an IgG1 mab against CS1 target, expressed on MM cells and interestingly, up regulated  by lenalidomide. His team are also targeting plasmacytoid dendritic cells (pDCs), key promoters of early myeloma cell colonization and expansion. Next generation proteosome inhibitors are in development including agents that target different proteosome components. Carfilzomib warranted a spec

ial mention due to the lack of peripheral neuropathy observed. Oral proteosome inhibitors are also under development and Dr Anderson concluded ‘I strongly believe the future of proteosome inhibitors is oral.’ Another exciting approach under development is to target protein homeostasis using aggresome inhibitors. The aggresome, is an intracellular organelle that forms when there is an accumulation of protein requiring disposal often seen if protein clearance is not fully effected by the proteosome. Hence inhibiting aggresome function is another method of inducing apoptosis. Furt

hermore, normal aggresome function is also mediated via HDAC activity providing a rationale for the use of HDAC inhibitors to disrupt this process.

Dr Andy Chantry
Senior Clinical Lecturer in Haematology/Honorary Consultant in Haematology
University of Sheffield/Sheffield Teaching Hospitals Foundation Trust